WO2019060719A1 - Méthodes et compositions pour le traitement d'une épidermolyse bulleuse - Google Patents

Méthodes et compositions pour le traitement d'une épidermolyse bulleuse Download PDF

Info

Publication number
WO2019060719A1
WO2019060719A1 PCT/US2018/052213 US2018052213W WO2019060719A1 WO 2019060719 A1 WO2019060719 A1 WO 2019060719A1 US 2018052213 W US2018052213 W US 2018052213W WO 2019060719 A1 WO2019060719 A1 WO 2019060719A1
Authority
WO
WIPO (PCT)
Prior art keywords
fluid
microvesicles
cells
cell
isolated
Prior art date
Application number
PCT/US2018/052213
Other languages
English (en)
Inventor
Evangelos V. BADIAVAS
Original Assignee
University Of Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/712,294 external-priority patent/US20180104186A1/en
Application filed by University Of Miami filed Critical University Of Miami
Priority to JP2020516903A priority Critical patent/JP2020534344A/ja
Priority to CA3076610A priority patent/CA3076610A1/fr
Priority to EA202090814A priority patent/EA202090814A1/ru
Priority to MX2020002777A priority patent/MX2020002777A/es
Priority to CN201880061329.5A priority patent/CN111182890A/zh
Priority to EP18859166.3A priority patent/EP3684336A4/fr
Priority to KR1020207010214A priority patent/KR20200088799A/ko
Priority to AU2018335788A priority patent/AU2018335788A1/en
Publication of WO2019060719A1 publication Critical patent/WO2019060719A1/fr
Priority to IL273407A priority patent/IL273407A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Abstract

La présente invention concerne des compositions et des méthodes pour le traitement d'une épidermolyse bulleuse.
PCT/US2018/052213 2017-09-22 2018-09-21 Méthodes et compositions pour le traitement d'une épidermolyse bulleuse WO2019060719A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2020516903A JP2020534344A (ja) 2017-09-22 2018-09-21 表皮水疱症を処置するための方法及び組成物
CA3076610A CA3076610A1 (fr) 2017-09-22 2018-09-21 Methodes et compositions pour le traitement d'une epidermolyse bulleuse
EA202090814A EA202090814A1 (ru) 2017-09-22 2018-09-21 Способы и композиции для лечения буллезного эпидермолиза
MX2020002777A MX2020002777A (es) 2017-09-22 2018-09-21 Metodos y composiciones para tratamiento de epidermolisis ampollosa.
CN201880061329.5A CN111182890A (zh) 2017-09-22 2018-09-21 用于治疗大疱性表皮松解症的方法和组合物
EP18859166.3A EP3684336A4 (fr) 2017-09-22 2018-09-21 Méthodes et compositions pour le traitement d'une épidermolyse bulleuse
KR1020207010214A KR20200088799A (ko) 2017-09-22 2018-09-21 수포성 표피박리증의 치료를 위한 방법 및 조성물
AU2018335788A AU2018335788A1 (en) 2017-09-22 2018-09-21 Methods and compositions for the treatment of epidermolysis bullosa
IL273407A IL273407A (en) 2017-09-22 2020-03-18 Methods and preparations for the treatment of epidermolysis bullosa

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/712,294 US20180104186A1 (en) 2013-03-13 2017-09-22 Methods and compositions for the treatment of epidermolysis bullosa
US15/712,294 2017-09-22

Publications (1)

Publication Number Publication Date
WO2019060719A1 true WO2019060719A1 (fr) 2019-03-28

Family

ID=65810503

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/052213 WO2019060719A1 (fr) 2017-09-22 2018-09-21 Méthodes et compositions pour le traitement d'une épidermolyse bulleuse

Country Status (10)

Country Link
EP (1) EP3684336A4 (fr)
JP (1) JP2020534344A (fr)
KR (1) KR20200088799A (fr)
CN (1) CN111182890A (fr)
AU (1) AU2018335788A1 (fr)
CA (1) CA3076610A1 (fr)
EA (1) EA202090814A1 (fr)
IL (1) IL273407A (fr)
MX (2) MX2020002777A (fr)
WO (1) WO2019060719A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022019325A1 (fr) * 2020-07-22 2022-01-27 国立大学法人大阪大学 Agent thérapeutique pour l'épidermolyse bulleuse dystrophique
WO2022040516A1 (fr) * 2020-08-21 2022-02-24 University Of Miami Compositions et méthodes de traitement faisant appel à des microvésicules issues de cellules souches mésenchymateuses dérivées de la moelle osseuse
EP3971440A1 (fr) 2020-09-21 2022-03-23 Brembo S.p.A. Bande de freinage d'un disque de frein à disque et disque de frein à disque
US11339125B2 (en) 2011-01-03 2022-05-24 The William M. Yarbrough Foundation Use of isothiocyanate functional surfactants as NRF2 inducers to treat epidermolysis bullosa simplex and related diseases
JP2022539228A (ja) * 2019-07-02 2022-09-07 インダストリー－ユニバーシティー コーペレイション ファンデーション ハンヤン ユニバーシティー エリカ キャンパス 植物エクソソームの大量生産方法
WO2023018891A1 (fr) * 2021-08-12 2023-02-16 Onconova Therapeutics, Inc. Méthodes et compositions pour traiter le cancer
WO2023064819A1 (fr) * 2021-10-12 2023-04-20 Eliksa Therapeutics, Inc. Méthodes de traitement de l'épidermolyse bulleuse avec des compositions de liquide amniotique acellulaire

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160184363A1 (en) * 2013-03-13 2016-06-30 University Of Miami Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
WO2016172598A1 (fr) * 2015-04-22 2016-10-27 The Broad Institute Inc. Exosomes et leurs utilisations
WO2017122095A1 (fr) * 2016-01-15 2017-07-20 Orbsen Therapeutics Limited Compositions d'exosomes à base de sdc2 et leurs procédés d'isolement et d'utilisation
US20170258845A1 (en) * 2013-09-16 2017-09-14 Agency For Science, Technology And Research Methods of Treating Graft Versus Host Disease (GVHD) or Epidermolysis Bullosa (EB)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138878A1 (fr) * 2014-03-13 2015-09-17 Research Institute At Nationwide Children's Hospital, Inc. Procédés d'administration d'un facteur de croissance épidermique de liaison à l'héparine à l'aide d'exosomes générés par des cellules souches
KR20170085010A (ko) * 2016-01-12 2017-07-21 주식회사 강스템바이오텍 고함량의 성장인자를 함유한 줄기세포 유래 엑소좀

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160184363A1 (en) * 2013-03-13 2016-06-30 University Of Miami Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
US20170258845A1 (en) * 2013-09-16 2017-09-14 Agency For Science, Technology And Research Methods of Treating Graft Versus Host Disease (GVHD) or Epidermolysis Bullosa (EB)
WO2016172598A1 (fr) * 2015-04-22 2016-10-27 The Broad Institute Inc. Exosomes et leurs utilisations
WO2017122095A1 (fr) * 2016-01-15 2017-07-20 Orbsen Therapeutics Limited Compositions d'exosomes à base de sdc2 et leurs procédés d'isolement et d'utilisation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GIMONA ET AL.: "Manufacturing of Human Extracellular Vesicle-Based Therapeutics for Clinical Use", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 18, no. 6, 3 June 2017 (2017-06-03), pages 1 - 19, XP055584380 *
MCBRIDE ET AL.: "Extracellular Vesicles as Biomarkers and Therapeutics in Dermatology: A Focus on Exosomes", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 137, no. 8, 23 June 2017 (2017-06-23), pages 1622 - 1629, XP055584384 *
See also references of EP3684336A4 *
SHABBIR ET AL.: "Mesenchymal Stem Cell Exosomes Induce Proliferation and Migration of Normal and Chronic Wound Fibroblasts, and Enhance Angiogenesis In Vitro", STEM CELLS AND DEVELOPMENT, vol. 24, no. 14, 13 April 2015 (2015-04-13), pages 1635 - 1647, XP055583096, DOI: doi:10.1089/scd.2014.0316 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11339125B2 (en) 2011-01-03 2022-05-24 The William M. Yarbrough Foundation Use of isothiocyanate functional surfactants as NRF2 inducers to treat epidermolysis bullosa simplex and related diseases
JP2022539228A (ja) * 2019-07-02 2022-09-07 インダストリー－ユニバーシティー コーペレイション ファンデーション ハンヤン ユニバーシティー エリカ キャンパス 植物エクソソームの大量生産方法
JP7274712B2 (ja) 2019-07-02 2023-05-17 インダストリー－ユニバーシティー コーペレイション ファンデーション ハンヤン ユニバーシティー エリカ キャンパス 植物エクソソームの大量生産方法
WO2022019325A1 (fr) * 2020-07-22 2022-01-27 国立大学法人大阪大学 Agent thérapeutique pour l'épidermolyse bulleuse dystrophique
WO2022018884A1 (fr) * 2020-07-22 2022-01-27 国立大学法人大阪大学 Agent thérapeutique destiné à l'épidermolyse bulleuse dystrophique
WO2022040516A1 (fr) * 2020-08-21 2022-02-24 University Of Miami Compositions et méthodes de traitement faisant appel à des microvésicules issues de cellules souches mésenchymateuses dérivées de la moelle osseuse
US20220072049A1 (en) * 2020-08-21 2022-03-10 University Of Miami Compositions and methods of treatment using microvesicles from bone marrow-derived mesenchymal stem cells
EP3971440A1 (fr) 2020-09-21 2022-03-23 Brembo S.p.A. Bande de freinage d'un disque de frein à disque et disque de frein à disque
WO2023018891A1 (fr) * 2021-08-12 2023-02-16 Onconova Therapeutics, Inc. Méthodes et compositions pour traiter le cancer
WO2023064819A1 (fr) * 2021-10-12 2023-04-20 Eliksa Therapeutics, Inc. Méthodes de traitement de l'épidermolyse bulleuse avec des compositions de liquide amniotique acellulaire

Also Published As

Publication number Publication date
EP3684336A4 (fr) 2021-06-02
KR20200088799A (ko) 2020-07-23
EA202090814A1 (ru) 2020-08-07
MX2020002777A (es) 2020-09-17
CN111182890A (zh) 2020-05-19
EP3684336A1 (fr) 2020-07-29
IL273407A (en) 2020-05-31
JP2020534344A (ja) 2020-11-26
AU2018335788A1 (en) 2020-03-19
MX2022015753A (es) 2023-01-19
CA3076610A1 (fr) 2019-03-28

Similar Documents

Publication Publication Date Title
US20230364150A1 (en) Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
US20180104186A1 (en) Methods and compositions for the treatment of epidermolysis bullosa
EP3684336A1 (fr) Méthodes et compositions pour le traitement d'une épidermolyse bulleuse
JP2021512595A (ja) 細胞療法に適した活性化誘導組織エフェクター細胞およびそれに由来する細胞外小胞
US20230330154A1 (en) Methods of treating systemic graft- versus-host disease with extracellular vesicles
US20230390341A1 (en) Methods and compositions for prevention and treatment of graft versus host disease
US20220072049A1 (en) Compositions and methods of treatment using microvesicles from bone marrow-derived mesenchymal stem cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18859166

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2018335788

Country of ref document: AU

Date of ref document: 20180921

Kind code of ref document: A

Ref document number: 2020516903

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3076610

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018859166

Country of ref document: EP

Effective date: 20200422